Update shared on 16 Nov 2025
Fair value Decreased 3.13%Analysts have adjusted their price target for Iovance Biotherapeutics from $8.00 to $7.75. This change reflects updated views on the company's growth trajectory and profitability outlook.
What's in the News
- Iovance Biotherapeutics reaffirmed revenue guidance for full-year 2025, projecting $250 to $300 million in Amtagvi sales. (Corporate Guidance)
- Interim data from the Phase 2 IOV-LUN-202 trial of lifileucel monotherapy in advanced nonsquamous NSCLC showed a 25.6% objective response rate, a disease control rate of 71.8%, and 2 complete responses among 39 patients. (Product-Related Announcements)
- Iovance Biotherapeutics filed a $350 million follow-on equity offering through an at-the-market offering of common stock. (Follow-on Equity Offering)
- Health Canada granted conditional market authorization for Amtagvi (lifileucel) for adults with unresectable or metastatic melanoma, based on positive results from the global Phase 2 C-144-01 trial. (Product-Related Announcements)
Valuation Changes
- Consensus Analyst Price Target has decreased slightly, moving from $8.00 to $7.75 per share.
- Discount Rate has edged up marginally from 7.04% to 7.06%.
- Revenue Growth is projected to rise, increasing from 43.3% to 45.6%.
- Net Profit Margin has improved significantly, rising from 1.8% to 9.0%.
- Future P/E ratio has fallen sharply, dropping from 345.8x to 66.4x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.